Home Featured Page 15

Featured

Latest

The Psychedelic Practitioner Issue 5: Groups in Practice

Psychedelic Policy Briefing: Week of June 16, 2026

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities

Out of This World: Why AI Belongs Beside the Therapist

International Conference on Assisted Dying and Other End of Life Care...

Michael Ryoshin Sapiro, PsyD – Truth Medicine, Psychedelics, and Living Your...

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic...

Navigators Film Club – Last Journey

Alexander Beiner – Psychedelics, Culture, and the Games We Play

Kyle Buller – How to Stay Grounded in Chaos: Breathwork, Psychedelics...

The Psychedelic News Feed: November 17 – 23, 2025

ARPA-H Launches $100M Effort to “Demystify” Mental Health and Catalyse Rapid-Acting...

EDITOR PICKS

The Psychedelic Practitioner Issue 5: Groups in Practice

Psychedelic Policy Briefing: Week of June 16, 2026

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Psychedelic Practitioner Issue 5: Groups in Practice

Psychedelic Policy Briefing: Week of June 16, 2026

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities

Out of This World: Why AI Belongs Beside the Therapist

Shroomski Melt

International Conference on Assisted Dying and Other End of Life Care...

Michael Ryoshin Sapiro, PsyD – Truth Medicine, Psychedelics, and Living Your...

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic...

Navigators Film Club – Last Journey

Alexander Beiner – Psychedelics, Culture, and the Games We Play

Kyle Buller – How to Stay Grounded in Chaos: Breathwork, Psychedelics...

The Psychedelic News Feed: November 17 – 23, 2025

ARPA-H Launches $100M Effort to “Demystify” Mental Health and Catalyse Rapid-Acting...

EDITOR PICKS

The Psychedelic Practitioner Issue 5: Groups in Practice

Psychedelic Policy Briefing: Week of June 16, 2026

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY